Abstracts tagged "epigenetics and salivary gland"

Abstract Number: 2830 • 2017 ACR/ARHP Annual Meeting
Epigenetic Cell Counting: A Novel Tool to Quantify Immune Cells in Salivary Glands Detects Robust Correlations of T Follicular Helper Cells with Immunopathology
Joel A.G. van Roon¹, Frederique M. Moret¹, Sofie L.M. Blokland¹, Aike A. Kruize², Gerben Bouma³, Andre van Maurik³, Sven Olek⁴, Ulrich Hoffmueller⁴ and Timothy R.D.J. Radstake⁵, ¹Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunoinflammation TAU, GlaxoSmithKline, Stevenage, United Kingdom, ⁴Epiontis GmbH, Berlin, Germany, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Histological analysis of salivary glands for decades has been a valuable tool in the characterization of patients with primary Sjögren’s syndrome (pSS) and non-Sjögren’s…
Abstract Number: 524 • 2014 ACR/ARHP Annual Meeting
Distinct Patterns of DNA Methylation in Labial Salivary Gland Tissue Based on Sjögren’s Syndrome Disease Status
Michael Cole¹, Xiaorong Shao¹, Diana Quach², Hong L. Quach², Lisa F. Barcellos² and Lindsey A. Criswell³, ¹Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ²Epidemiology, University of California, Berkeley, Berkeley, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s Syndrome (SS, OMIM #270150) is a chronic, multi-system autoimmune disease characterized by progressive destruction of the exocrine glands, with subsequent mucosal and conjunctival…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].